Improving Cell Line Development Efficiency With AbZelectPRO™

Reaching clinical trials with your innovative biologic or ADC is paramount, but cell line development bottlenecks can stall progress. Abzena's AbZelectPRO™ platform cuts through these delays, reducing timelines to just 10 weeks from gene sequence to research cell bank (RCB).

This revolutionary approach optimizes the vector, host cell line, and process, yielding high-performing, stable Mammalian CHO cell lines for efficient protein and vaccine production up to 8g/L. Early generation of diverse, fast-growing pools allows for in-depth characterization and proactive risk mitigation, ensuring a smooth path to IND filing.

Backed by Abzena's deep expertise and ICH-compliant analytics platform, you gain invaluable insights and a comprehensive report for seamless IND integration. Don't let cell line development hold you back – review the advantages of this innovative, accelerated CLD platform and unlock the potential of your biologics and bioconjugates.